Mr. Erez Tetro reports

VVT MED CLOSES SECOND TRANCHE OF PRIVATE PLACEMENT OF UNITS; OVER $1.8M IN TOTAL PROCEEDS RAISED

On Sept. 10, 2026, VVT Med Inc. completed the second tranche of its previously announced non-brokered private placement offering.

Including the first tranche of the offering, the company has issued a total of 7,540,414 units at a price of 25 cents per unit for gross proceeds of $1,885,103.50. The offering comprised three tranches, with Tranche 2 issuing 3,277,760 units at a price of 25 cents per unit for gross proceeds of $819,440. The company closed the first tranche of this offering on April 22, 2026, and currently intends to complete a third and final tranche on the same terms by the end of September, 2026.

Each unit consists of one common share of the company and one-half of one common share purchase warrant. Each whole warrant is exercisable into one common share at an exercise price of 37.5 cents per warrant share for a period of 24 months from the date of issuance.

The net proceeds from the offering will be used to support expanded U.S. and global commercialization efforts, product manufacturing to accommodate anticipated demand, working capital, and general corporate purposes. The securities issued pursuant to the offering will be subject to a four-month hold period from the date of issuance in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

In connection with the closing of Tranche 2, the company paid certain eligible finders a cash fee of up to 8 per cent of the gross proceeds raised in respect of the offering from subscribers introduced by such finders to the company for a total of $5,200. In addition, the company issued to eligible finders such number of finder warrants equal to 8 per cent of the number of units sold under the offering to subscribers introduced by such finders to the company for a total of 20,800 finder warrants. Each finder warrant will entitle the holder to acquire one common share at an exercise price of 37.5 cents per share for a period of 24 months following the date of issuance.

The completion of any additional tranche of the offering remains subject to receipt of all necessary regulatory approvals, including acceptance by the TSX-V. There can be no assurance that any additional tranche of the offering will be completed on the terms described, or at all.

Debt settlement

Further to its news releases dated Aug. 21, 2026, and Sept. 1, 2026, the company is pleased to announce that it has closed its previously announced debt settlement with various creditors of the company.

Pursuant to the debt settlement, the company entered into debt settlement agreements with the creditors to settle an aggregate of $212,939.76 of debt owed by the company to the creditors by issuing an aggregate of 741,096 common shares, of which 280,000 were issued at a deemed price of 25 cents per share and 461,096 were issued at a deemed price of 31 cents per share.

The completion of the debt settlement remains subject to final acceptance by the TSX-V. All securities issued pursuant to the debt settlement have been issued pursuant to a prospectus exemption and are subject to a four-month-and-one-day hold period that expires on Jan. 11, 2027.

About VVT Med Inc.

VVT is the only FDA-cleared (U.S. Food and Drug Administration), stand-alone company offering non-thermal, non-tumescent (NT-NT) varicose vein treatment technology. VVT's catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia or downtime. Addressing the widest range of vein diameters, VVT's solutions empower physicians to treat both the medical and aesthetic aspects of vein disease through a cost-efficient, simultaneous sclerosant injection and blood aspiration process. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.